Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROCEPT BioRobotics (PRCT) Total Liabilities (2020 - 2025)

PROCEPT BioRobotics (PRCT) has disclosed Total Liabilities for 6 consecutive years, with $142.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Liabilities rose 7.9% to $142.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $142.2 million, a 7.9% increase, with the full-year FY2025 number at $142.2 million, up 7.9% from a year prior.
  • Total Liabilities was $142.2 million for Q4 2025 at PROCEPT BioRobotics, up from $131.3 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $206.3 million in Q2 2021 to a low of $68.2 million in Q3 2021.
  • A 5-year average of $120.2 million and a median of $122.2 million in 2023 define the central range for Total Liabilities.
  • Peak YoY movement for Total Liabilities: tumbled 65.23% in 2022, then soared 63.33% in 2023.
  • PROCEPT BioRobotics' Total Liabilities stood at $69.9 million in 2021, then skyrocketed by 60.52% to $112.3 million in 2022, then rose by 10.43% to $124.0 million in 2023, then grew by 6.32% to $131.8 million in 2024, then grew by 7.9% to $142.2 million in 2025.
  • Per Business Quant, the three most recent readings for PRCT's Total Liabilities are $142.2 million (Q4 2025), $131.3 million (Q3 2025), and $127.3 million (Q2 2025).